Laurus Labs 미래 성장

Future 기준 확인 4/6

Laurus Labs (는) 각각 연간 55.6% 및 15.6% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 56.2% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 13.3% 로 예상됩니다.

주요 정보

55.6%

수익 성장률

56.2%

EPS 성장률

Pharmaceuticals 수익 성장	17.5%
매출 성장률	15.6%
향후 자기자본 수익률	13.3%
애널리스트 커버리지	Good
마지막 업데이트	07 Nov 2024

최근 미래 성장 업데이트

Laurus Labs Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Jan 27

Recent updates

Laurus Labs (NSE:LAURUSLABS) Is Due To Pay A Dividend Of ₹0.40

Oct 28

Laurus Labs (NSE:LAURUSLABS) Takes On Some Risk With Its Use Of Debt

Oct 26

Here's Why It's Unlikely That Laurus Labs Limited's (NSE:LAURUSLABS) CEO Will See A Pay Rise This Year

Jul 05

Laurus Labs Limited's (NSE:LAURUSLABS) Price In Tune With Revenues

Jul 03

Laurus Labs' (NSE:LAURUSLABS) Dividend Will Be ₹0.40

Apr 28

Laurus Labs Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Jan 27

Is Laurus Labs (NSE:LAURUSLABS) A Risky Investment?

Dec 01

Laurus Labs (NSE:LAURUSLABS) Is Paying Out Less In Dividends Than Last Year

Oct 22

These 4 Measures Indicate That Laurus Labs (NSE:LAURUSLABS) Is Using Debt Reasonably Well

Jul 06

Laurus Labs (NSE:LAURUSLABS) Is Paying Out A Dividend Of ₹1.20

Apr 30

Is Laurus Labs (NSE:LAURUSLABS) A Risky Investment?

Dec 18

Is Laurus Labs Limited (NSE:LAURUSLABS) Expensive For A Reason? A Look At Its Intrinsic Value

Sep 27

I Ran A Stock Scan For Earnings Growth And Laurus Labs (NSE:LAURUSLABS) Passed With Ease

Nov 12

Laurus Labs (NSE:LAURUSLABS) Has Affirmed Its Dividend Of ₹0.80

Oct 30

A Look At The Intrinsic Value Of Laurus Labs Limited (NSE:LAURUSLABS)

Oct 05

Should You Be Adding Laurus Labs (NSE:LAURUSLABS) To Your Watchlist Today?

Aug 10

Laurus Labs (NSE:LAURUSLABS) Seems To Use Debt Quite Sensibly

Jul 23

Is Laurus Labs Limited (NSE:LAURUSLABS) Worth ₹547 Based On Its Intrinsic Value?

Jun 06

수익 및 매출 성장 예측

NSEI:LAURUSLABS - 애널리스트의 미래 추정치 및 과거 재무 데이터 (INR Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
3/31/2027	74,517	7,982	3,301	11,211	13
3/31/2026	64,614	5,975	1,323	10,019	13
3/31/2025	55,442	3,444	225	10,205	13
9/30/2024	50,532	1,311	-3,277	2,489	N/A
6/30/2024	50,540	1,482	N/A	N/A	N/A
3/31/2024	50,408	1,606	-126	6,657	N/A
12/31/2023	49,821	1,879	N/A	N/A	N/A
9/30/2023	53,320	3,678	2,870	12,248	N/A
6/30/2023	56,834	5,637	N/A	N/A	N/A
3/31/2023	60,406	7,901	37	9,939	N/A
12/31/2022	60,845	9,176	N/A	N/A	N/A
9/30/2022	55,684	8,683	13	8,393	N/A
6/30/2022	51,960	8,374	N/A	N/A	N/A
3/31/2022	49,356	8,275	343	9,111	N/A
12/31/2021	49,227	8,937	N/A	N/A	N/A
9/30/2021	51,823	10,128	-1,705	7,112	N/A
6/30/2021	51,177	10,532	N/A	N/A	N/A
3/31/2021	48,135	9,836	442	7,330	N/A
12/31/2020	42,407	7,971	N/A	N/A	N/A
9/30/2020	36,819	5,977	1,548	5,427	N/A
6/30/2020	32,555	4,120	N/A	N/A	N/A
3/31/2020	28,317	2,553	1,252	3,474	N/A
12/31/2019	26,277	1,883	N/A	N/A	N/A
9/30/2019	24,276	1,326	1,613	3,538	N/A
6/30/2019	23,035	923	N/A	N/A	N/A
3/31/2019	22,919	938	434	2,977	N/A
12/31/2018	22,170	957	N/A	N/A	N/A
9/30/2018	21,665	1,127	N/A	N/A	N/A
6/30/2018	21,168	1,453	N/A	N/A	N/A
3/31/2018	20,562	1,676	N/A	3,425	N/A
12/31/2017	19,687	1,917	N/A	N/A	N/A
9/30/2017	19,954	2,019	N/A	N/A	N/A
6/30/2017	19,733	2,014	N/A	N/A	N/A
3/31/2017	19,046	1,881	N/A	3,320	N/A
3/31/2016	17,776	1,337	N/A	1,820	N/A
3/31/2015	13,266	684	N/A	-647	N/A
3/31/2014	11,597	972	N/A	1,212	N/A

애널리스트 미래 성장 예측

수입 대 저축률: LAURUSLABS 의 연간 예상 수익 증가율( 55.6% )이 saving rate( 6.7% 보다 높습니다. ).

수익 vs 시장: LAURUSLABS 의 연간 수익( 55.6% ) Indian 시장( 18.1% 보다 빠르게 성장할 것으로 예상됩니다. 18.1% 연간).

고성장 수익: LAURUSLABS 의 수입은 향후 3년 동안 상당히 증가할 것으로 예상됩니다.

수익 대 시장: LAURUSLABS 의 수익(연간 15.6% ) Indian 시장( 10.5% 보다 빠르게 성장할 것으로 예상됩니다. 10.5% 연간).

고성장 수익: LAURUSLABS 의 수익(연간 15.6% )은 연간 20% 보다 느리게 증가할 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: LAURUSLABS 의 자본 수익률은 3년 내에 최저 수준이 될 것으로 예상됩니다( 13.3 %).

성장 기업 발견

기업 분석 및 재무 데이터 현황

데이터	마지막 업데이트(UTC 시간)
기업 분석	2024/12/22 02:52
장 마감 주가	2024/12/20 00:00
수익	2024/09/30
연간 수익	2024/03/31

데이터 소스

기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
회사 재무	10년	손익 계산서 현금 흐름표 대차 대조표	SEC 양식 10-K SEC 양식 10-Q
애널리스트 컨센서스 추정치	+3년	재무 예측 애널리스트 목표가	애널리스트 연구 보고서 Blue Matrix
시장 가격	30년	주식 가격 배당금, 분할 및 액션	ICE 시장 데이터 SEC 양식 S-1
소유권	10년	최대 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
관리	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발 사항	10년	회사 공지 사항	SEC 양식 8-K

* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처가 사용된 예입니다.

명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 여기에서 자세히 알아보세요.

분석 모델 및 눈송이

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.

Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.

산업 및 부문 메트릭

업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 확인할 수 있습니다.

애널리스트 출처

Laurus Labs Limited 23 애널리스트 중 13 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.

분석가	교육기관
Prashant Nair	Ambit Capital
Nitin Bhasin	Ambit Capital
null null	Antique Stockbroking Ltd.

Laurus Labs 미래 성장

Future 기준 확인 4/6

주요 정보

최근 미래 성장 업데이트

Consensus EPS estimates fall by 12%

Laurus Labs Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Consensus EPS estimates fall by 34%

Price target increased by 7.2% to ₹371

Consensus EPS estimates fall by 10%

Price target decreased by 11% to ₹382

Recent updates

Consensus EPS estimates fall by 12%

Laurus Labs (NSE:LAURUSLABS) Is Due To Pay A Dividend Of ₹0.40

First half dividend of ₹0.40 announced

Laurus Labs (NSE:LAURUSLABS) Takes On Some Risk With Its Use Of Debt

Second quarter 2025 earnings: EPS and revenues miss analyst expectations

Laurus Labs Limited Approves Interim Dividend for the Financial Year 2024- 2025

Laurus Labs Limited to Report Q2, 2025 Results on Oct 24, 2024

Laurus Labs Limited Appoints Ramesh Subrahmanian as A Non-Executive Independent Director

First quarter 2025 earnings: EPS and revenues miss analyst expectations

Laurus Labs Limited to Report Q1, 2025 Results on Jul 25, 2024

Laurus Labs Limited Announces Board Appointments

Here's Why It's Unlikely That Laurus Labs Limited's (NSE:LAURUSLABS) CEO Will See A Pay Rise This Year

Laurus Labs Limited's (NSE:LAURUSLABS) Price In Tune With Revenues

Full year 2024 earnings: EPS misses analyst expectations

Less than half of directors are independent

Less than half of directors are independent

Laurus Labs' (NSE:LAURUSLABS) Dividend Will Be ₹0.40

Final dividend reduced to ₹0.40

Laurus Labs Limited, Annual General Meeting, Jul 11, 2024

Full year 2024 earnings: EPS misses analyst expectations

Laurus Labs Limited Approves Board Changes

Laurus Labs Limited to Report Q4, 2024 Results on Apr 25, 2024

Laurus Labs Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Laurus Labs Limited to Report Q3, 2024 Results on Jan 24, 2024

Is Laurus Labs (NSE:LAURUSLABS) A Risky Investment?

Consensus EPS estimates fall by 34%

Upcoming dividend of ₹0.40 per share at 0.4% yield

Price target increased by 7.2% to ₹371

Laurus Labs (NSE:LAURUSLABS) Is Paying Out Less In Dividends Than Last Year

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Laurus Labs Limited Approves Interim Dividend, Payable on or After November 09, 2023

Laurus Labs Limited to Report Q2, 2024 Results on Oct 20, 2023

Laurus Labs Limited (NSEI:LAURUSLABS) agreed to acquire an additional 14.54% stake in Laurus Bio Private Limited from one of the Promoters, non-executive director, his family members and few Employee/ex-Employee shareholders for approximately INR 720 million.

Investor sentiment improves as stock rises 16%

Consensus EPS estimates fall by 10%

New minor risk - Profit margin trend

First quarter 2024 earnings released: EPS: ₹0.46 (vs ₹4.68 in 1Q 2023)

These 4 Measures Indicate That Laurus Labs (NSE:LAURUSLABS) Is Using Debt Reasonably Well

Full year 2023 earnings: EPS and revenues miss analyst expectations

Laurus Labs Limited (NSEI:LAURUSLABS) signed an investment agreement to acquire additional 7.24% stake in Immunoadoptive Cell Therapy Private Limited for INR 800 million.

Upcoming dividend of ₹1.20 per share at 0.6% yield

Price target decreased by 11% to ₹382

Laurus Labs (NSE:LAURUSLABS) Is Paying Out A Dividend Of ₹1.20

Full year 2023 earnings: EPS and revenues miss analyst expectations

Price target decreased by 10% to ₹470

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Laurus Labs Limited to Report Q3, 2023 Results on Jan 30, 2023

Is Laurus Labs (NSE:LAURUSLABS) A Risky Investment?

Laurus Labs Limited announced that it expects to receive INR 38.998 million in funding from Ethan Energy India Private Limited

Insufficient new directors

Upcoming dividend of ₹0.80 per share

Price target decreased to ₹574

Laurus Labs Limited Approves Interim Dividend for the Financial Year 2022-2023, Payable on or After November 15, 2022

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Laurus Labs Limited to Report Q2, 2023 Results on Oct 21, 2022

Is Laurus Labs Limited (NSE:LAURUSLABS) Expensive For A Reason? A Look At Its Intrinsic Value

Is Laurus Labs (NSE:LAURUSLABS) Using Too Much Debt?

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Laurus Labs Limited to Report Q1, 2023 Results on Jul 27, 2022

Investor sentiment deteriorated over the past week

Laurus Labs (NSE:LAURUSLABS) Has A Somewhat Strained Balance Sheet

Full year 2022 earnings: Revenues and EPS in line with analyst expectations

Upcoming dividend of ₹1.20 per share

Laurus Labs (NSE:LAURUSLABS) Is Paying Out A Larger Dividend Than Last Year

Full year 2022 earnings: Revenues and EPS in line with analyst expectations

Insufficient new directors

Laurus Labs Limited to Report Q4, 2022 Results on Apr 28, 2022

Laurus Labs (NSE:LAURUSLABS) Seems To Use Debt Quite Sensibly